Effectiveness of Bebtelovimab Against the Risk of Hospitalization and Death Owing to the Omicron BA.4/BA.5 and BQ.1/BQ.1.1 Subvariants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Chest
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of Bebtelovimab Against Hospitalization and Death From the Omicron BA.4/BA.5 and BQ.1/BQ.1.1 Subvariants
Chest 2023 Jun 17;[EPub Ahead of Print], X Wang, FA Fadel, S Huang, GL Sacha, P Bartley, A Duggal, DY LinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.